Align Technology (ALGN) is back in focus after a run of analyst upgrades tied to its recent earnings performance, with revenue and net income both showing year over year growth and valuation metrics attracting fresh investor attention.
See our latest analysis for Align Technology.
At a share price of US$171.87, Align’s recent 7 day share price return of 3.37% and year to date share price return of 10.15% sit against a 1 year total shareholder return of 12.08%, while the 3 year and 5 year total shareholder returns of 48.02% and 71.41% declines show how recent momentum contrasts with a much tougher longer term experience.
If this kind of earnings driven move has your attention, it may be a good moment to scan the market for other specialised healthcare names using our healthcare AI stock screener, including 37 healthcare AI stocks
With earnings beats, year over year growth in revenue and net income, and the shares trading at what some analysts see as a discount to their price targets, is Align still mispriced, or is the market already accounting for the next leg of growth?
Most Popular Narrative: 11.2% Overvalued
According to the most followed narrative, Align's fair value sits at $154.62 versus the latest close of $171.87, which puts the current price above that reference point while still reflecting a business built on clinical credibility and premium positioning.
Align Technology is no longer proving that clear aligners work. It is proving that premium orthodontics can endure in a cost-sensitive world. For investors, ALGN represents a business built on medical credibility as much as consumer appeal. If Align continues to align innovation with clinical rigor, it may retain its leadership not through price competition, but through outcomes that justify the premium.
The narrative leans heavily on durable demand for Invisalign, disciplined margins and a valuation anchored to projected revenue and earnings trends rather than headline growth alone. It blends assumptions about pricing resilience, international expansion and profitability to justify its fair value, and connects them through a discount rate that reflects Align's maturity and sector risks.
Result: Fair Value of $154.62 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this narrative could be challenged if premium pricing in clear aligners comes under pressure, or if competitors gain share faster than expected in key markets.
Find out about the key risks to this Align Technology narrative.
Another View: Cash Flows Point to Undervaluation
While the popular narrative tags Align as 11.2% overvalued at a fair value of $154.62, our DCF model points the other way. On that framework, the shares at $171.87 sit about 18.8% below an estimated future cash flow value of $211.60. So which story do you trust more: earnings multiples or long term cash flows?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Align Technology for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Mixed messages on value and risk so far. If that leaves you curious, take a closer look at the data yourself and weigh both sides with 2 key rewards and 1 important warning sign
Ready for more investment ideas?
If Align has sharpened your focus, do not stop here. The market is full of other opportunities worth putting on your radar before the next move.
- Target potential mispricing by scanning for quality companies trading below their implied worth using the 62 high quality undervalued stocks.
- Strengthen your income stream by checking out companies with payout profiles that stand out through the 13 dividend fortresses.
- Sleep easier at night by focusing on businesses with sturdier finances using the solid balance sheet and fundamentals stocks screener (40 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com